Loading...

Home
ETF
GLMD

GLMD

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

GLMD News

Galmed Pharmaceuticals Receives Nasdaq Compliance Notice

Jan 30 2026seekingalpha

Galmed Pharmaceuticals Receives Nasdaq Compliance Notice

Jan 30 2026PRnewswire

Galmed Pharmaceuticals Faces Nasdaq Compliance Challenge

Jan 30 2026Newsfilter

Galmed Pharmaceuticals to Initiate Phase 1/2 Trial of Aramchol and Regorafenib in 2026

Dec 08 2025PRnewswire

Galimedix Reports Excellent Phase 1 Results for GAL-101 with No Adverse Events

Dec 04 2025Globenewswire

Galmed Secures New Patent for Aramchol, Extending Protection to 2042

Dec 04 2025PRnewswire

Galmed Pharmaceuticals Reports $19.2M Cash Position, Advancing Clinical Development

Dec 01 2025PRnewswire

Galmed Pharmaceuticals Announces $1.9 Million Loss in Q3; Showcases Advancements in Pipeline

Nov 28 2025NASDAQ.COM

Galmed Pharmaceuticals Reports $2M Net Loss for Q3 2025

Nov 26 2025Newsfilter

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 26 2025PRnewswire

Galmed Reports Significant Top Line Findings from AM-001 Study of Aramchol Meglumine

Nov 18 2025Newsfilter

Significant Drivers Appear in Oncology, Synthetic Biology, and M&A Activity as Markets Begin Trading

Nov 17 2025Newsfilter

Galmed Reports Promising Findings from Oncology Mechanism of Action Studies: A Combination of Aramchol, Stivarga®, and Metformin Significantly Kills GI Tumor Cells Both In-vivo and In-vitro

Nov 17 2025Newsfilter

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 28 2025PRnewswire

Galmed Unveils Digital Asset Management Plan to Improve Capital Efficiency and Boost Shareholder Value

Aug 25 2025Newsfilter

Palo Alto Shares Rise Approximately 7%; Check Out 20 Stocks Making Moves in Premarket Trading

Aug 19 2025Benzinga